Browse studies
Find your next paid study
28 recruiting studies matching your filters
Phase 1
A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine th…
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Estimated
~$10 – $6,250
Brigham and Women's HospitalNCT06062745
Phase 1
A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors
The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. T…
Neuroendocrine CarcinomaNeuroendocrine Tumors
Estimated
~$10 – $7,500
Peter Hosein, MDNCT06889493
Phase 1
PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a nove…
Neuroendocrine Carcinoma MetastaticPancreatic Tumors
Estimated
~$10 – $6,250
Abramson Cancer Center at Penn MedicineNCT07114939
Phase 1
A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in pati…
Advanced Solid TumorMetastatic Solid TumorRefractory Solid Tumor+7 more
Estimated
~$10 – $8,750
Circle PharmaNCT06577987